SERINC2 has previously been reported to be up-regulated in a variety of cancers and has been considered a biomarker after multiple bioinformatics analyses for early diagnosis or prognosis prediction in lung adenocarcinoma [18,19], ovarian cancer [20], and low-grade glioma (LGG) [21]. Here, SERINC2 is linked to lung adenocarcinoma.